Items Tagged ‘stage IV’

September 15th, 2015

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Xalkori™ (crizotinib).  Alectinib was previously granted Breakthrough Therapy Designation by the FDA for people with ALK-positive […]

View full entry

Tags: alectinib, ALK inhibitor, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


September 10th, 2015

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer

By

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies showed sustained survival benefit. Both trials showed an estimated 18-month overall survival (OS) rate of 27% (CheckMate […]

View full entry

Tags: CheckMate, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV